Changing the conversation about obesity For both researchers, one of the most important impacts of GLP-1 drugs may be how they reshape public understanding of obesity itself
The FDA approved semaglutide (Wegovy) for chronic weight management in 2021, marking a significant expansion of GLP-1 RA use beyond glucose control
No countdown timers, no urgency messaging, no forced prompts
For years, the question was often whether people with T1D should be using these medications at all
First, lack of exposure is possible, as we lacked information on patient compliance with prescribed treatments and potential lack of medication dispensed at hospitals, however as medication compliance is similar across all three groups and we defined exposure as redeemed prescriptions, ensuring that the medication was actively collected by the patient, systematic misclassification is unlikely
It is important to note that no randomized trial has included a head-to-toe comparison between these two drugs, to evaluate their relative roles in preventing kidney failure and death among patients with diabetes and CKD, especially in patients with varying baseline kidney function, albuminuria severity, and comorbidities such as cardiovascular disease or obesity. Read More About Kidney Disease Lisa Foster Lisa Foster is a mom of 3 daughters and 1 perfect grandchild, a puzzle lover, writer and HealthTree advocate
